Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **HSPC023 protein pseudogene** (ENSG00000213247) is classified as a pseudogene, a segment of genomic DNA resembling a known gene (here, HSPC023 protein) but generally considered nonfunctional due to mutations that prevent protein expression. Pseudogenes originate by gene duplication or retrotransposition, after which disabling mutations accumulate[1][6][4]. Although once labeled “junk DNA,” some pseudogenes produce noncoding RNA transcripts capable of regulating gene expression indirectly, for example by acting as decoys for microRNAs (miRNAs) or participating in other gene regulatory networks; however, there is no evidence that the HSPC023 protein pseudogene is functional in this manner[1][3][6]. It is not recognized as a therapeutic target, receptor, enzyme, transporter, or transcription factor; nor does it have any known aliases or biomarker/drug associations[4]. The “is_incorrect” flag is set to true because pseudogenes are not considered actionable therapeutic targets and generally lack sufficient structural/functional information to populate standard drug discovery databases[5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HSPC023 protein pseudogene (HSPC023).